Decoding AChR-Positive Vs MuSK-Positive Myasthenia Gravis Pathophysiology to Guide Mechanism-Specific Development
- Differentiating the immunologic mechanisms underlying AChR-positive versus MuSK-positive MG
- Understand subtype-specific pathophysiology to better align complement, FcRn and B-cell approaches with appropriate patient subtypes
- Connecting disease biology to therapeutic mechanism selection and responder prediction to strengthen subtype-driven clinical trial design and reduce misaligned mechanism deployment